CE-Ventures Backs Aptadir Therapeutics in €40 Million Seed Round

CE-Ventures has backed Aptadir Therapeutics in a €40 million seed round, a financing that ranks among the largest seed rounds in European biotech, according to a report published by markets.businessinsider.com.

The size of the round sets the deal apart. Seed financings in European biotech rarely reach the €40 million mark, and the figure positions Aptadir Therapeutics in rare company at the earliest stage of its corporate life.

CE-Ventures, the venture arm associated with the United Arab Emirates' Crescent Enterprises group, led the backing of the therapeutics developer. The identity of any co-investors participating in the round was not disclosed in the report.

The €40 million commitment gives Aptadir Therapeutics substantial early-stage capital at a moment when biotech funding conditions remain demanding. For a seed-stage company, a check of this size typically signals investor conviction in both the underlying science and the founding team, though the report did not detail Aptadir's specific drug programs or development pipeline.

The transaction also underscores a broader pattern: investors with Gulf-based capital, including CE-Ventures, have been deploying increasing amounts into European life sciences. The Aptadir deal adds a concrete data point to that trend, with a Middle East-rooted investor writing one of Europe's largest biotech seed checks.

Aptadir Therapeutics, the recipient of the financing, did not have its pipeline, targets or clinical stage described in the announcement carried by markets.businessinsider.com. The company's name now enters the ranks of European biotech's best-funded seed-stage firms on the strength of this single round.

For European biotech, the deal carries signaling value beyond the two parties involved. Large seed rounds often set reference points for subsequent financings in the sector, and a €40 million early-stage commitment may give other founders and investors a fresh benchmark when pricing comparable deals.

The financing's final structure — whether it combines equity with other instruments — was not specified in the report. What is confirmed is the headline figure, the lead backer and the scale of the round relative to the European market.

The next question for Aptadir Therapeutics is deployment. How the company allocates €40 million across research, hiring and preclinical or clinical work will determine whether the round's headline size translates into therapeutic progress — and whether CE-Ventures' early conviction pays off at later stages of financing.